Deucartumab monotherapy has new indications domestically.

On December 25th, the First Pharmaceuticals announced that its injection drug pertuzumab was approved for a new indication in China, for the treatment of unresectable or metastatic hormone receptor-positive, HER2-low expression or HER2-suppressed expression adult breast cancer patients who have progressed after one or more prior endocrine therapies in the metastatic setting. It became the first HER2-targeted therapy for patients who have progressed after one or more prior endocrine therapies in the metastatic setting.